Abstracts

461 – A Humanized Microfluidics BBB Model With Recirculation for CNS ARV Distribution Evaluation

Background Antiretroviral (ARV) efficacy in the central nervous system (CNS) is hindered by poor penetration across the blood–brain barrier (BBB). Current in vitro BBB models are limited by non-human or immortalized cells, few relevant cell types, and static conditions that restrict pharmacokinetic/pharmacodynamic (PK/PD) sampling. We developed a microfluidic BBB model with primary human brain cells…

219 – Identification of Factors That Mediate Nuclear Retention of Intron-Containing HIV-1 Transcripts

Background HIV-1 replication depends on the Rev-mediated nuclear export of unspliced (US) and partially spliced (PS) viral RNAs through the CRM1 pathway. HIV-1 transcripts are generated from a single promoter, undergo extensive alternative splicing, and are highly enriched in adenosine nucleotides. While completely spliced (CS) viral RNAs are exported independently of Rev, the export of…

233 – In Addition to Antiviral Properties, Some Antiretrovirals Have an Anti-NLRP3 Inflammasome Activity

Background NLRP3 inflammasome activation leads to IL-1β and IL-18 production and secretion, responsible of long-term chronic inflammation. The significance of NLRP3 inflammasome in the CVDs-related inflammation and other aging diseases has been extensively demonstrated. Moreover, NLRP3 inflammasome signaling has been shown to be one of the links between HIV-1 infection and atherosclerotic cardiovascular disease. Certain…

532 – Safety of Cabotegravir + Rilpivirine Long-Acting Regimen Among PLWH With Previous HBV Exposure

Background Cabotegravir + Rilpivirine long-acting regimen (CARLA) has no anti-HBV activity and is not recommended for PLWH with active HBV co-infection. No data exist on its hepatic safety among PLWH with resolved HepB (rHepB), especially among those with isolated HBcAb+ (IsHBcAb+).   Methods Retrospective multicenter observational study including PLWH on CARLA. Primary aim was to demonstrate hepatic…

554 – Third-Generation InSTI VH4524184 (VH-184) Has an Enhanced Resistance Profile vs Bictegravir

Background Integrase strand transfer inhibitors (INSTIs) are a cornerstone of HIV-1 treatment due to their potency, durability, and high barrier to resistance. Maintaining and improving these attributes are critical to meet the evolving needs of persons with HIV. VH4524184 (VH-184) is a third-generation INSTI with potential as a long-acting injectable that has demonstrated potent antiviral…

1038 – Differential Risk Reduction of Gonorrhea and Chlamydia Among DoxyPEP Users Reporting High Adherence

Background DoxyPEP has high prevention efficacy for sexually transmitted infections (STI) among cisgender men and transgender people. Previous work from Magnet Sexual Health Clinic at San Francisco AIDS Foundation (Magnet) found that only 61% of DoxyPEP users reported using the medication consistently within 72 hours of sexual exposures. The STI risk reduction of DoxyPEP may…

869 – HBV Burden and Poor Vaccine-Induced Protection in Adolescents With HIV-1 in West and Central Africa

Background In 2009, WHO has recommended to introduce HBV vaccine into the national immunization programs of endemic countries. Furthermore, HBV testing is recommended in all individuals living with HIV worldwide. This study sought to ascertain the burden of HIV/HBV co-infection and the HBV vaccine-induced immunisation in adolescents living with HIV-1 (ALHIV) receiving care in four…

335 – Changes in the HIV-1 Reservoir in South African HIV+ to HIV+ Kidney Transplant Recipients

Background Examining the HIV-1 reservoir during periods of immune “reset” may uncover pathways that could lead to novel strategies for activation and eventual clearance of latently infected cells. Lymphocyte-depleting agents such as anti-thymocyte globulin (ATG) provide a unique real-world in vivo model to examine how immune depletion and reconstitution might influence HIV reservoir changes.  Methods…

633 – Immune-Activation Markers and Subsequent Cancer Onset in People With HIV (PWH): A Case-Control Study

Background The INSIGHT group conducted large international trials (ESPRIT, FIRST, SMART, START) evaluating different antiretroviral therapy (ART) strategies in PWH. Collectively, these studies established the benefits of continuous use of ART, including reductions in the incidence of certain cancers. Leveraging these well-characterized cohorts, we conducted a case-control study to evaluate circulating immune activation biomarkers predictive…

1093 – At-Home Urine Tenofovir Testing is Feasible and Correlates With Adherence in Dried Blood Spots

Background At-home antiretroviral therapy (ART) adherence testing offers a scalable and convenient strategy to support remote HIV care. Urine point-of-care (POC) tenofovir assays and tenofovir-diphosphate (TFV-DP) levels in dried blood spots (DBS) both objectively assess adherence, but their correlation and acceptability in self-collected samples have not been evaluated. We assessed the ability of at-home urine…